Australia vs Iceland: Share of the population living with HIV receiving antiretroviral therapy
Australia
87.9%
in 2023
Iceland
88.2%
in 2024
Australia rank
27th
Iceland rank
24th
Share of the population living with HIV receiving antiretroviral therapy over time
- Australia
- Iceland
How they compare
Iceland currently reports 88.2% against 87.9% in Australia, a difference of 0.3%.
The two have swapped places 6 times across 34 shared years of data; in 1990 it was Iceland ahead.
Australia ranks 27th and Iceland ranks 24th of 149 countries.
Australia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Australia | Iceland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 12.1% | 3.6% | 8.5% | Australia |
| 2000s | 53.8% | 50.5% | 3.3% | Australia |
| 2010s | 75.3% | 72.7% | 2.6% | Australia |
| 2020s | 85.7% | 85.1% | 0.6% | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Australia or Iceland?
- Iceland, at 88.2% against 87.9% in Australia as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Australia and Iceland?
- 0.3%, with Iceland ahead.
- How many years of comparable data are there for Australia and Iceland?
- 34 years are reported by both, from 1990 to 2023.
- How do Australia and Iceland rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Australia ranks 27th and Iceland ranks 24th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.